Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ITGB1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ITGB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ITGB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ITGB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ITGB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ITGB1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ITGB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ITGB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ITGB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ITGB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190307613 | Breast | IDC | regulation of protein localization to plasma membrane | 17/1434 | 104/18723 | 2.28e-03 | 2.09e-02 | 17 |
GO:000189413 | Breast | IDC | tissue homeostasis | 34/1434 | 268/18723 | 2.54e-03 | 2.28e-02 | 34 |
GO:190437513 | Breast | IDC | regulation of protein localization to cell periphery | 19/1434 | 125/18723 | 3.06e-03 | 2.60e-02 | 19 |
GO:00431126 | Breast | IDC | receptor metabolic process | 23/1434 | 166/18723 | 4.04e-03 | 3.25e-02 | 23 |
GO:003563313 | Breast | IDC | maintenance of blood-brain barrier | 8/1434 | 35/18723 | 4.22e-03 | 3.31e-02 | 8 |
GO:00324125 | Breast | IDC | regulation of ion transmembrane transporter activity | 33/1434 | 267/18723 | 4.38e-03 | 3.40e-02 | 33 |
GO:009030312 | Breast | IDC | positive regulation of wound healing | 11/1434 | 59/18723 | 4.70e-03 | 3.61e-02 | 11 |
GO:00426923 | Breast | IDC | muscle cell differentiation | 44/1434 | 384/18723 | 4.77e-03 | 3.66e-02 | 44 |
GO:00324096 | Breast | IDC | regulation of transporter activity | 37/1434 | 310/18723 | 4.77e-03 | 3.66e-02 | 37 |
GO:00347644 | Breast | IDC | positive regulation of transmembrane transport | 28/1434 | 219/18723 | 5.19e-03 | 3.86e-02 | 28 |
GO:000170113 | Breast | IDC | in utero embryonic development | 42/1434 | 367/18723 | 5.85e-03 | 4.24e-02 | 42 |
GO:004349111 | Breast | IDC | protein kinase B signaling | 27/1434 | 211/18723 | 5.92e-03 | 4.26e-02 | 27 |
GO:00511463 | Breast | IDC | striated muscle cell differentiation | 34/1434 | 283/18723 | 6.00e-03 | 4.31e-02 | 34 |
GO:00726599 | Breast | IDC | protein localization to plasma membrane | 34/1434 | 284/18723 | 6.33e-03 | 4.47e-02 | 34 |
GO:001603224 | Breast | DCIS | viral process | 73/1390 | 415/18723 | 3.40e-12 | 6.88e-10 | 73 |
GO:001905824 | Breast | DCIS | viral life cycle | 59/1390 | 317/18723 | 4.05e-11 | 5.74e-09 | 59 |
GO:004440323 | Breast | DCIS | biological process involved in symbiotic interaction | 49/1390 | 290/18723 | 4.70e-08 | 2.89e-06 | 49 |
GO:005090021 | Breast | DCIS | leukocyte migration | 54/1390 | 369/18723 | 1.22e-06 | 4.78e-05 | 54 |
GO:000931422 | Breast | DCIS | response to radiation | 62/1390 | 456/18723 | 2.56e-06 | 8.87e-05 | 62 |
GO:001063121 | Breast | DCIS | epithelial cell migration | 51/1390 | 357/18723 | 4.83e-06 | 1.43e-04 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGB1 | SNV | Missense_Mutation | | c.2050N>G | p.Gln684Glu | p.Q684E | P05556 | protein_coding | tolerated(0.27) | benign(0.006) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | | c.445A>C | p.Met149Leu | p.M149L | P05556 | protein_coding | deleterious(0.03) | benign(0.398) | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
ITGB1 | SNV | Missense_Mutation | | c.826T>C | p.Phe276Leu | p.F276L | P05556 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-BH-A1F6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | rs758287253 | c.1474N>T | p.Asn492Tyr | p.N492Y | P05556 | protein_coding | deleterious(0) | possibly_damaging(0.494) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
ITGB1 | insertion | Nonsense_Mutation | novel | c.1500_1501insCAGCTCTAATCCTCATAACAGTCCTGTGCCTAGAA | p.Glu501GlnfsTer3 | p.E501Qfs*3 | P05556 | protein_coding | | | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ITGB1 | insertion | Nonsense_Mutation | novel | c.560_561insCTCTAGATGACCTTCTTTGATTTTAGAGGCCTCTTAGTGG | p.Val188SerfsTer3 | p.V188Sfs*3 | P05556 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ITGB1 | SNV | Missense_Mutation | novel | c.1982N>A | p.Cys661Tyr | p.C661Y | P05556 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
ITGB1 | SNV | Missense_Mutation | | c.337N>G | p.Gln113Glu | p.Q113E | P05556 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ITGB1 | SNV | Missense_Mutation | novel | c.1480G>C | p.Gly494Arg | p.G494R | P05556 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | novel | c.2216N>C | p.Gly739Ala | p.G739A | P05556 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | FIRATEGRAST | FIRATEGRAST | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | 131I-radretumab | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109621 | ABITUZUMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL2108061 | VOLOCIXIMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | JSM 6427 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 385612210 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL1201607 | NATALIZUMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | F200 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | R1295 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | GLPG0187 | GLPG-0187 | |